CLDI

0.47755.45%
GT

Guy Travis Clifton

Chief Medical Officer

Dr. Guy Travis Clifton, MD., is Chief Medical Officer of Calidi Biotherapeutics, Inc. from April 2025 and served as its Consultant & Advisor since April 2025 until 2025. He serves as Advisory Partner at Texas Next Capital. He served as Chief Development Office at Incendia Therapeutics (formerly known as Parthenon Therapeutics Inc.) since November 2022 until 2024. He was Co-Founder and Head of Clinical Sciences of Incendia Therapeutics (formerly known as Parthenon Therapeutics Inc.) since 2022 until 2024 and served as its Chief Medical Officer until April 2022 and served as its Interim Chief Medical Officer since April 2022 until 2022. He is a practicing surgical oncologist and clinical trialist with oncology drug development and clinical practice experience. He completed General Surgery residency at BAMC and Complex General Surgical Oncology fellowship at University of Texas MD Anderson Cancer Center. He has deployed multiple times overseas to combat zones and within the US for COVID-19 response with the US Army. He has experience in translational cancer immunotherapy research with intimate experience with the design, initiation and execution of cancer immunotherapy clinical trials. He has over 60 peer-reviewed oncology publications, over 120 published abstracts and multiple book chapters. He received a BS in Chemistry from the United States Military Academy at West Point and a Doctor of Medicine from Vanderbilt University Medical School. He completed his residency in General Surgery from the Brooke Army Medical Center.

公司职务